Lixte Biotechnology Holdings Inc Sustainability Reports
A clinical-stage biopharmaceutical company focused on developing protein phosphatase 2A (PP2A) inhibitors to enhance cancer treatment efficacy. Following a 2026 merger, it is pivoting toward AI-related power infrastructure.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 5493004HPIB1PBNQ3L69
3 reports from 2013 to 2015
